共 50 条
- [31] Allogeneic hematopoietic cell transplantation with reduced-intensity conditioning following FLAMSA for primary refractory or relapsed acute myeloid leukemiaANNALS OF HEMATOLOGY, 2013, 92 (10) : 1389 - 1395Schneidawind, DominikFedermann, BirgitFaul, ChristophVogel, WichardKanz, LotharBethge, Wolfgang Andreas
- [32] Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remissionBLOOD, 2013, 122 (10) : 1813 - 1821Walter, Roland B.Buckley, Sarah A.Pagel, John M.Wood, Brent L.Storer, Barry E.Sandmaier, Brenda M.Fang, MinGyurkocza, BoglarkaDelaney, ColleenRadich, Jerald P.Estey, Elihu H.Appelbaum, Frederick R.
- [33] Mega-dose decitabine conditioning and prophylactic donor lymphocyte infusion for patients with relapsed/refractory AML with active disease at the time of allogeneic haematopoietic cell transplantation: A multicenter prospective phase II studyBRITISH JOURNAL OF HAEMATOLOGY, 2024, 205 (05) : 1910 - 1920Lv, MengYan, Chen-HuaMa, RuiHe, YunZhang, Yuan-YuanWang, Zhi-DongChen, Yu-HongHan, WeiKong, JunHan, Ting-TingLiu, JingZheng, HaoMo, Xiao-DongSun, Yu-QianWang, YuXu, Lan-PingZhang, Xiao-HuiHuang, Xiao-Jun
- [34] Peripheral Blood WT1 Expression Predicts Relapse in AML Patients Undergoing Allogeneic Stem Cell TransplantationBIOMED RESEARCH INTERNATIONAL, 2014, 2014Malagola, MicheleSkert, CristinaRuggeri, GiuseppinaTurra, AlessandroRibolla, RossellaCancelli, ValeriaCattina, FedericaAlghisi, ElisaBernardi, SimonaPerucca, SimoneDi Palma, AndreaBorlenghi, ErikaPagani, ChiaraRossi, GiuseppeCaimi, LuigiRusso, Domenico
- [36] Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AMLBLOOD, 2018, 132 (16) : 1703 - 1713Thol, FelicitasGabdoulline, RazifLiebich, AlessandroKlement, PiroskaSchiller, JohannesKandziora, ChristianHambach, LotharStadler, MichaelKoenecke, ChristianFlintrop, MaditaPankratz, MiraWichmann, MartinNeziri, BlerinaBuettner, KonstantinHeida, BennetKlesse, SabrinaChaturvedi, AnuharKloos, ArnoldGoehring, GudrunSchlegelberger, BrigitteGaidzik, Verena I.Bullinger, LarsFiedler, WalterHeim, AlbertHamwi, IyasEder, MatthiasKrauter, JuergenSchlenk, Richard F.Paschka, PeterDoehner, KonstanzeDoehner, HartmutGanser, ArnoldHeuser, Michael
- [37] Real world results of venetoclax combined with hypomethylating agents in relapsed/refractory AMLEUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2021, 25 (21) : 6557 - 6565Ucar, M. A.Ozet, G.Koyuncu, M. B.Sonmez, M.Akidan, O.Ayli, M.Yildirim, M.Pehlivan, M.Akkurt, D. M.Sahin, H.Guvenc, B.Okan, VTiftik, E. N.Akdeniz, A.Dincyurek, H. D.Gunes, A. K.Dagdas, S.Acar, H., IUcar, H. K.Tombak, A.
- [38] Comparison of Cytogenetic Clonal Evolution Patterns following Allogeneic Hematopoietic Transplantation versus Conventional Treatment in Patients at Relapse of AMLBIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2010, 16 (12) : 1649 - 1657Bacher, UlrikeHaferlach, TorstenAlpermann, TamaraZenger, MelanieKroger, NicolausBeelen, Dietrich W.Kern, WolfgangSchnittger, SusanneHaferlach, Claudia
- [39] Randomized Phase III SIERRA Trial of 131I-Apamistamab Before Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care for Relapsed/Refractory AMLJOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (02) : 201 - 213Gyurkocza, BoglarkaNath, RajneeshSeropian, StuartChoe, HannahLitzow, Mark R.Abboud, CamilleKoshy, NebuStiff, PatrickTomlinson, BenjaminAbhyankar, SunilForan, JamesHari, ParameswaranChen, GeorgeAl-Kadhimi, ZaidKebriaei, PartowSabloff, MitchellOrozco, Johnnie J.Jamieson, KatarzynaSilverman, MargaridaVan Besien, KoenSchuster, MichaelLaw, Arjun DattLarkin, KarilynPandit-Taskar, NeetaRowley, Scott D.Munshi, PashnaCook, RachelLevy, Moshe Y.Lazarus, Hillard M.Sandmaier, Brenda M.Pagel, John M.Reddy, VijayMacdougall, JamesMcnamara, KathleenSpross, JenniferHaeuber, ElainaVusirikala, MadhuriNahar, AkashDesai, AvinashGiralt, Sergio